Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2025

One-pot Synthesis of *trans*-2,3-Diaminoindolines through 2,3-Diamination of Electrophilic Indolines

Yuito Kobori¹, Keisuke Tokushige¹ and Takumi Abe*¹

¹Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1, Tsushima-naka, Kita-ku, Okayama 7008530, Japan E-mail: t-abe@okayama-u.ac.jp

Supporting Information

General methods ·····	······ S2
Experimental procedures and spectra data for obtained products	··· S3–S24
References	······S25
¹ H and ¹³ C NMR spectra	· S26–S91

General methods. Column chromatography was carried out using silica gel (WAKO Gel 75–150 mesh, WAKO Co., Ltd.). Preparative tin-layer chromatography was performed with silica gel plates (60F-254). Melting points (mp) were recorded with a Yamato melting point apparatus model MP-21 and are uncorrected. IR spectra were measured with a HORIBA fourier transform infrared spectrometer FT-720, and absorbance frequencies are reported in reciprocal centimeters (cm⁻¹). NMR experiments were performed with JEOL JNM-ECZ600R (¹H NMR: 600 MHz, ¹³C NMR: 151 MHz) spectrometer and Varian NMR system 600 (¹H NMR:600 MHz, ¹³C NMR: 151 MHz) spectrometer and Varian NMR system 600 (¹H NMR:600 MHz, ¹³C NMR: 151 MHz). ¹H NMR spectra were referenced to a solvent signal (CDCl₃: 7.26 ppm, DMSO-*d*₆: 2.50 ppm). ¹³C NMR spectra were referenced to a solvent signal (CDCl₃: 7.26 ppm, DMSO-*d*₆: 39.5). Signal multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd), doublet of doublets (ddd) septet (sept), broad (br). High-resolution MS spectra were recorded with a Brucker microTOF mass spectrometers (ESI-TOF-MS). Reactions were monitored by thin layer chromatography (TLC) carried out on a silica gel plates (60F-254) and visualized under UV illumination at 254 or 365 nm depending on the compounds.

Compound number of amines to be used in this reaction



Figure S1.

ſ

Synthesis of N-protected indoles S1

The *N*-protected indoles **S1** as *N*-tosylindoles (**S1a**, **S1e–S1j**), *N*-benzenesulfonylindole (**S1b**), *N*-(4-methoxybenzenesulfonyl)indole (**S1c**) and *N*-(4-phenylbenzenesulfonyl)indole (**S1d**) were prepared by reported method.^[2] All substrates were used as received from commercial suppliers (Sigma-Aldrich, Kanto Chemical, TCI, Wako and Nacalai tesque) and all reagents were weighed and handled in air at room temperature. Analytical data are in accordance with the literature values.^[2]

N-protected indoles	S1a : (R ¹ = Ts,	R ² = H)
	S1b : (R ¹ = Bs,	R ² = H)
	S1c : (R ¹ = MBs,	R ² = H)
	S1d : (R ¹ = PhBs,	R ² = H)
\mathbb{R}^2	S1e : (R ¹ = Ts,	R ² = 5-CI)
6 X N 7 R ¹	S1f : (R ¹ = Ts,	R ² = 5-Br)
	S1g : (R ¹ = Ts,	R ² = 5-Me)
	S1h : (R ¹ = Ts,	R ² = 5-MeO)
	S1i : (R ¹ = Ts,	R ² = 4-CI)
	S1j : (R ¹ = Ts,	R ² = 6-CI)
	s1k : (R ¹ = Ts,	R ² = 7-aza)
$T_{S} = \begin{cases} 0 = S = 0 \\ B_{S} = 0 \\ M_{e} \end{cases} B_{s} = \begin{cases} 0 = S = 0 \\ S = 0 \\ M_{e} \end{cases}$	0= S =0 MBs =	OHe OHe

Figure S2.

Synthesis of trans-2-hydroxyindoline-3-trirthylammonium bromide (HITAB) 1

The *trans*-2-hydroxyindoline-3-triethylammonium bromides (HITAB) **1** were prepared by reported method.^[3] All reagents were weighed and handled in air at room temperature. Analytical data are in accordance with the literature values $(1a^{[3a]}, 1b, 1f, 1j^{[3b]}, 1c^{[3c]}, 1e, and 1h^{[3d]})$.



Figure S3.

Synthesis of trans-2,3-diaminoindolines 4

Scheme S2: Typical procedure for Table 1



This reaction was performed with the synthesis of **4aec** (R = 2c), **4aeg** (R = 2g), **4aeh** (R = 2h), and **4aei** (R = 2i). To a mixture of **1** (469 mg, 1.0 equiv., 1.0 mmol) and **2e** (0.108 mL, 1.0 equiv., 1.0 mmol) in AcOEt (5.0 mL, 0.2 M) was added Et₃N (0.277 mL, 2.0 equiv. 2.0 mmol). The mixture was stirred at reflux for 2 h. After the whole was cooled to room temperature, **2** (1.05 equiv., 1.05 mmol) was added to the mixture and stirred at reflux further 1 h. After the whole was cooled to room temperature, H₂O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by recrystallization or silica gel column chromatography.

Scheme S3: General procedure A



This reaction was performed with the synthesis of **4adg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2d$), **4bdg** ($R^1 = Bs$, $R^2 = H$, $R^3 = 2d$), **4cdg** ($R^1 = MBs$, $R^2 = H$, $R^3 = 2d$), **4edg** ($R^1 = Ts$, $R^2 = 5$ -Cl, $R^3 = 2d$), **4fdg** ($R^1 = Ts$, $R^2 = 5$ -Br, $R^3 = 2d$), **4hdg** ($R^1 = Ts$, $R^2 = 5$ -MeO, $R^3 = 2d$), **4jdg** ($R^1 = Ts$, $R^2 = 6$ -Cl, $R^3 = 2d$), **4ajg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2j$), **4akg** ($R^1 = Ts$, $R^2 = 5$ -MeO, $R^3 = 2k$), **4alg** ($R^1 = Ts$, $R^2 = 6$ -Cl, $R^3 = 2d$), **4aig** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2j$), **4akg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2k$), **4alg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2l$), **4amg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2n$), **4ang** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2n$), **4aog** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2o$), **4apg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2p$), **4aqg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2q$), **4afg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2f$), **4agg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2g$), **4ahg** ($R^1 = Ts$, $R^2 = H$, $R^3 = 2d$), **4ahg** ($R^1 = Ts$, $R^2 = H$, $R^3 =$

To a mixture of **1** (469 mg, 1.0 equiv., 1.0 mmol) and **2** (1.0 equiv., 1.0 mmol) in AcOEt (5.0 mL, 0.2 M) was added Et_3N (0.277 mL, 2.0 equiv. 2.0 mmol). The mixture was stirred at reflux for 1–6 h. After the whole was cooled to room temperature, **2g** (0.088 mL, 1.05 equiv., 1.05 mmol) was added to the mixture and stirred at reflux further 1 h. After the whole was cooled to room temperature, H₂O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by recrystallization or silica gel column chromatography.

Scheme S4: General procedure B



This reaction was performed with the synthesis of **4ddg** (R^1 = PhBs, R^2 = H), **4gdg** (R^1 = Ts, R^2 = 5-Me), and **4idg** (R^1 = Ts, R^2 = 4-Cl).

To a solution of **S1** (1.0 equiv., 1.0 mmol) and H_2O (0.18 mL, 10 equiv., 10 mmol) in acetone (5.0 mL, 0.2 M) was added NBS (196 mg, 1.1 equiv., 1.1 mmol). The mixture was stirred at room temperature until the complete disappearance of starting material indicated by TLC. Then Et₃N (0.152 mL, 1.1 equiv. 1.1 mmol) was added to the mixture and stirred further 0.5 h. After the mixture was concentrated *in vacuo*, the residue was dissolved in AcOEt (5.0 mL, 0.2 M). To this mixture was added aniline **2d** (0.091 mL, 1.0 equiv., 1.0 mmol) and Et₃N (0.277 mL, 2.0 equiv., 2.0 mmol). The mixture was stirred at reflux for 6 h. After the whole was cooled to room temperature, pyrrolidine **2d** (0.086 mL, 1.05 equiv., 1.05 mmol) was added to the mixture and stirred at reflux further 1 h. After the whole was cooled to room temperature, H₂O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by recrystallization or silica gel column chromatography.



The reaction was performed according to the typical procedure for Table S1 using 0.108 mL (1.05 mmol) of **2c**. The residue was purified by silica-gel column chromatography using hexane/AcOEt (20/1-10/1 [v/v]) and

recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-4aec (306 mg, 0.63 mmol, 63% yield) as a white solid.

White solid (306 mg, 0.63 mmol, 63% yield; mp 116–118 °C); IR (KBr) v: 3367, 3057, 3032, 2943, 2866, 2812, 1350, 1167, 754, 698 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.87 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.40–7.42 (m, 3H), 7.35 (t, J = 7.5 Hz, 2H), 7.26–7.30 (m, 3H), 7.22 (d, J = 8.4 Hz, 2H), 7.06–7.11 (m, 2H), 6.95 (d, J = 8.4 Hz, 2H), 6.83 (t, J = 7.2 Hz, 1H), 5.16 (d, J = 3.0 Hz, 1H), 5.06 (d, J = 3.6 Hz, 1H), 4.06 (d, J = 13.8 Hz, 1H), 3.81 (d, J = 13.2 Hz, 1H), 2.39 (s, 3H), 1.77 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 149.6, 144.4, 141.9, 139.9, 135.4, 130.1, 129.9, 129.3, 128.8, 128.5, 128.4, 127.3, 127.2, 126.3, 124.3, 118.0, 115.7, 114.1, 82.5, 65.0, 46.7, 32.3, 21.6; HRMS (ESI) *m*/*z*: [M+Na]⁺ Calcd for C₂₉H₂₉N₃O₂SNa 506.1878; Found 506.1875.

trans-N-Methyl-N-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4aeg)



The reaction was performed according to the typical procedure for Table S1 using 0.086 mL (1.05 mmol) of **2g**. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4aeg** (409 mg, 0.91 mmol, 91% yield) as a white solid.

White solid (409 mg, 0.91 mmol, 91% yield; mp 128–130 °C, dec.); IR (KBr) v: 3057, 3024, 2968, 2916, 2868, 2827, 1350, 1167, 752, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.76 (d, *J* = 7.8 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 2H), 7.37 (ddd, *J* = 8.4, 6.6, 1.8 Hz, 1H), 7.29 (t, *J* = 8.7 Hz, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 7.06–7.10 (m, 2H), 6.93 (d, *J* = 7.8 Hz, 2H), 6.81 (t, *J* = 7.2 Hz, 1H), 5.21 (d, *J* = 1.2 Hz, 1H), 4.87 (s, 1H), 2.84–2.88 (m, 2H), 2.59–2.63 (m, 2H), 2.34 (s, 3H), 1.71–1.80 (m, 4H), 1.64 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 149.5, 143.9, 142.7, 136.4, 130.1, 129.65, 129.65, 129.4, 127.6, 126.7, 124.5, 117.6, 116.7, 113.4, 86.3, 65.4, 47.2, 32.3, 23.8, 21.6; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₉N₃O₂SNa 470.19878; Found 470.1883.





The reaction was performed according to the typical procedure for Table S1 using 0.104 mL (1.05 mmol) of **2h**. The residue was purified by silica-gel column chromatography using hexane/chloroform (1/2 [v/v]) and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4aeh** (85 mg, 0.18 mmol, 18% yield) as a white solid.

White solid (85 mg, 0.18 mmol, 18% yield; mp 154–156 °C, dec.); IR (KBr) v: 3068, 3051, 3012, 2937, 2912, 2848, 2816, 1354, 1169, 750, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.77 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.36 (td, *J* = 8.4, 1.8 Hz, 1H), 7.29 (t, *J* = 9.0 Hz, 2H), 7.15 (d, *J* = 7.8 Hz, 2H), 7.07 (td, *J* = 7.5, 0.6 Hz, 1H), 7.05 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 7.8 Hz, 2H), 6.81 (t, *J* = 7.2 Hz, 1H), 4.89 (s, 1H), 4.83 (d, *J* = 2.4 Hz, 1H), 2.57–2.67 (m, 4H), 2.34 (s, 3H), 1.68 (s, 3H), 1.52–1.63 (m, 4H), 1.45-1.49 (m, 2H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 149.7, 144.0, 142.9, 136.3, 130.1, 130.0, 129.7, 129.3, 127.6, 126.1, 124.4, 117.6, 116.8, 113.8, 90.2, 65.8, 49.3, 32.4, 26.6, 24.5, 21.6; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₇H₃₁N₃O₂SNa 484.2035; Found 484.2039.





The reaction was performed according to the typical procedure for Table S1 using 0.091 mL (1.05 mmol) of **2i**. The residue was purified by silica-gel column chromatography using hexane/acetone (5/1-3/1 [v/v]) and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4aei** (18 mg, 0.04 mmol, 4% yield) as a white solid.

White solid (18 mg, 0.04 mmol, 4% yield; mp 146–148 °C, dec.); IR (KBr) v: 2958, 2924, 2852, 1346, 1167, 748, 694 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.76 (d, *J* = 7.8 Hz, 1H), 7.64 (d, *J* = 9.0 Hz, 2H), 7.38 (td, *J* = 8.4, 1.5 Hz, 1H), 7.30 (t, *J* = 8.7 Hz, 2H), 7.16 (d, *J* = 7.8 Hz, 2H), 7.10 (td, *J* = 7.5, 0.6 Hz, 1H), 7.07 (d, *J* = 7.2 Hz, 1H), 6.99 (d, *J* = 8.4 Hz, 2H), 6.83 (t, *J* = 7.2 Hz, 1H), 4.92 (s, 1H), 4.84 (d, *J* = 1.8 Hz, 1H), 3.66–3.75 (m, 4H), 2.61–2.70 (m, 4H), 2.35 (s, 3H), 1.70 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 149.3, 144.1, 142.6, 136.1, 130.1, 129.61, 129.61, 129.3, 127.5, 126.1, 124.5, 117.7, 116.7, 113.6, 88.7, 67.2, 65.1, 48.3, 32.2, 21.5; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₉N₃O₃SNa 486.1827; Found 486.1829.

trans-N-Phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4adg)



The reaction was performed according to the general procedure A using 0.091 mL (1.0 mmol) of **2d** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4adg** (383 mg, 0.88 mmol, 88% yield) as a white solid.

White solid (383 mg, 0.88 mmol, 88% yield; mp 126–128 °C, dec.); IR (KBr) v: 3419, 3086, 3014, 2970, 2910, 2881, 2844, 1348, 1157, 756, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.73 (d, *J* = 8.4 Hz, 1H), 7.41 (d, *J* = 9.0 Hz, 2H), 7.38 (td, *J* = 8,7, 1.5 Hz, 1H), 7.19–7.21 (m, 3H), 7.11 (td, *J* = 7.5, 0.6 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.77 (t, *J* = 7.5 Hz, 1H), 6.42 (d, *J* = 7.8 Hz, 2H), 5.15 (s, 1H), 4.50 (d, *J* = 7.2 Hz, 1H), 2.76–2.80 (m, 2H), 2.54–2.57 (m, 2H), 2.41 (d, *J* = 7.2 Hz, 1H), 2.38 (s, 3H), 1.71–1.78 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.6, 143.8, 142.7, 135.1, 132.5, 130.3, 129.5, 129.4, 127.4, 125.6, 125.4, 118.2, 117.7, 113.3, 85.7, 59.8, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₇N₃O₂SNa 456.1722; Found 456.1722.

trans-N-Phenyl-1-(phenylsulfonyl)-2-(pyrrolidin-1-yl)indolin-3-amine (4bdg)



The reaction was performed according to the general procedure A using 455 mg (1.0 mmol) of **1b** and 0.091 mL (1.0 mmol) of **2d** for 3 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4bdg** (345 mg, 0.82 mmol, 82% yield) as a white solid.

White solid (345 mg, 0.82 mmol, 82% yield; mp 130–132 °C, dec.); IR (KBr) v: 3423, 3072, 3041, 2974, 2929, 2877, 2848, 1350, 1169, 750, 721 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, *J* = 7.8 Hz, 1H), 7.54 (d, *J* = 7.8 Hz, 2H) 7.52 (t, *J* = 7.2 Hz, 1H), 7.39 (td, *J* = 8.4, 1.2 Hz, 1H), 7.31 (t, *J* = 8.1 Hz, 2H), 7.21 (d, *J* = 7.2 Hz, 1H), 7.20 (d, *J* = 7.8 Hz, 2H), 7.12 (td, *J* = 7.8, 1.2 Hz, 1H), 6.77 (t, *J* = 7.2 Hz, 1H), 6.44 (d, *J* = 7.8 Hz, 2H), 5.18 (s, 1H), 4.50 (d, *J* = 7.2 Hz, 1H), 2.77–2.80, (m, 2H), 2.55–2.58 (m, 2H), 2.40 (d, *J* = 7.2 Hz, 1H), 1.72–1.76 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.5, 142.5, 138.0, 133.0, 132.5, 130.3. 129.5, 128.9, 127.4, 125.6, 125.5, 118.2, 117.7, 113.3, 85.9, 59.8, 47.5, 23.5; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₄H₂₅N₃O₂SNa 442.1565; Found 442.1566.

trans-1-((4-Methoxyphenyl)sulfonyl)-N-phenyl-2-(pyrrolidin-1-yl)indolin-3-amine (4cdg)



The reaction was performed according to the general procedure A using 485 mg (1.0 mmol) of **1c** and 0.091 mL (1.0 mmol) of **2d** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4cdg** (333 mg, 0.74 mmol, 74% yield) as a white solid.

White solid (333 mg, 0.74 mmol, 74% yield; mp 126–128 °C, dec.); IR (KBr) v: 3413, 3072, 3026, 2970, 2931, 2871, 2841, 1346, 1259, 1157, 1024, 754, 698 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, *J* = 7.8 Hz, 1H), 7.45 (d, *J* = 9.6 Hz, 2H), 7.38 (td, *J* = 8.4, 1.2 Hz, 1H), 7.21 (d, *J* = 7.2 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.11 (td, *J* = 7.2, 0.9 Hz, 1H), 6.77 (t, *J* = 7.2 Hz, 1H), 6.75 (d, *J* = 9.0 Hz, 2H), 6.46 (d, *J* = 7.2 Hz, 2H), 5.14 (s, 1H), 4.49 (d, *J* = 7.2 Hz, 1H), 3.82 (s, 3H), 2.77–2.79 (m, 2H), 2.54–2.57 (m, 2H), 2.50 (d, *J* = 6.6 Hz, 1H), 1.71–1.78 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 163.0, 145.7, 142.8, 132.5, 130.3, 129.8, 129.47, 129.47, 125.5, 125.3, 118.1, 117.8, 113.9, 113.2, 85.6, 59.8, 55.7, 47.5, 23.4; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₇N₃O₃SNa 472.1671; Found 472.1671.

trans-1-([1,1'-Biphenyl]-4-ylsulfonyl)-N-phenyl-2-(pyrrolidin-1-yl)indolin-3-amine (4ddg)



The reaction was performed according to the general procedure B using 333 mg (1.0 mmol) of **1d** and 0.091 mL (1.0 mmol) of **2d**. The residue was purified by silica-gel column chromatography using hexane/AcOEt (10/1 [v/v]) and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4ddg** (136 mg, 0.27 mmol, 27% yield) as a pale purple solid.

Pale purple solid (136 mg, 0.27 mmol, 27% yield; mp 134–136 °C, dec.); IR (KBr) v: 3392, 3057, 3026, 2964, 2924, 2877, 2848, 1352, 1167, 756, 694 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.78 (d, J = 7.8 Hz, 1H), 7.57–7.59 (m, 4H), 7.52 (d, J = 8.4 Hz, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.43 (d, J = 7.2 Hz, 1H), 7.41 (td, J = 7.2, 0.9 Hz, 1H), 7.22 (d, J = 6.6 Hz, 1H), 7.18 (t, J = 7.2 Hz, 2H), 7.14 (td, J = 7.2, 0.9 Hz, 1H), 6.76 (t, J = 7.2 Hz, 1H), 6.40 (d, J = 7.2 Hz, 2H), 5.20 (s, 1H), 4.51 (d, J = 6.6 Hz, 1H), 2.79–2.82 (m, 2H), 2.57–2.59 (m, 2H), 2.48 (d, J = 6.6 Hz, 1H), 1.75–1.77 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.53, 145.47, 142.5, 138.9,

136.5, 132.5, 130.3, 129.4, 129.2, 128.7, 127.8, 127.20, 127.20, 125.53, 125.47, 118.1, 117.7, 113.2, 85.7, 59.8, 47.5, 23.5; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₃₀H₂₉N₃O₂SNa 518.1878; Found 518.1883.

trans-5-Chloro-*N*-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4edg)



The reaction was performed according to the general procedure A using 504 mg (1.0 mmol) of **1e** and 0.091 mL (1.0 mmol) of **2d** for 3 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4edg** (426 mg, 0.91 mmol, 91% yield) as a white solid.

White solid (426 mg, 0.91 mmol, 91% yield; mp 131–133 °C, dec.); IR (KBr) v: 3408, 3055, 3028, 2972, 2922, 2860, 2823, 1352, 1169, 1090, 754, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.66 (d, *J* = 9.0 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.34 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.21 (t, *J* = 7.5 Hz, 2H), 7.18 (d, *J* = 2.4 Hz, 1H), 7.12 (d, *J* = 7.8 Hz, 2H), 6.79 (t, *J* = 7.5 Hz, 1H), 6.41 (d, *J* = 7.8 Hz, 2H), 5.15 (s, 1H), 4.47 (d, *J* = 7.8 Hz, 1H), 2.76–2.79 (m, 2H), 2.53–2.56 (m, 2H), 2.41 (s, 3H), 1.73–1.78 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.3, 144.1, 141.3, 134.9, 134.1, 130.44, 130.40, 129.7, 129.5, 127.4, 125.8, 118.8, 118.5, 113.3, 86.1, 59.6, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆ClN₃O₂SNa 490.1332, 492.1302; Found 490.1328, 492.1297.

trans-5-Bromo-N-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4fdg)



The reaction was performed according to the general procedure A using 548 mg (1.0 mmol) of **1f** and 0.091 mL (1.0 mmol) of **2d** for 3 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4fdg** (469 mg, 0.92 mmol, 92% yield) as a pale beige solid.

Pale beige solid (469 mg, 0.92 mmol, 92% yield; mp 130–132 °C, dec.); IR (KBr) v: 3408, 3055, 3028, 2970, 2922, 2860, 2821, 1352, 1167, 754, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.61 (d, J = 8.4 Hz, 1H), 7.49 (dd, J = 6.0, 2.4 Hz, 1H), 7.41 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 1.8 Hz, 1H), 7.21 (t, J = 7.8 Hz, 2H), 7.12 (d, J = 7.8 Hz, 2H), 6.79 (t, J = 7.5 Hz, 1H), 6.41 (d, J = 7.2 Hz, 2H), 5.15 (s, 1H), 4.47 (d, J = 7.2 Hz, 1H), 2.76–2.79 (m, 2H), 2.53–2.56 (m, 2H), 2.41 (s, 3H), 1.74–1.77 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.3, 144.1,

141.8, 134.9, 134.5, 133.3, 129.7, 129.5, 128.7, 127.4, 119.2, 118.5, 117.9, 113.3, 86.1, 59.5, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆BrN₃O₂SNa 534.0827, 536.0806; Found 534.0827, 536.0810.

trans-5-Methyl-*N*-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4gdg)



The reaction was performed according to the general procedure B using 285 mg (1.0 mmol) of **S1g** and 0.091 mL (1.0 mmol) of **2d**. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4gdg** (171 mg, 0.38 mmol, 38% yield) as a beige solid.

Beige solid (171 mg, 0.38 mmol, 38% yield; mp 127–129 °C, dec.); IR (KBr) v: 3406, 3051, 3026, 2970, 2922, 2856, 2839, 2806, 1348, 1165, 752, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.60 (d, *J* = 8.4 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.20 (t, *J* = 7.2 Hz, 2H), 7.18 (d, *J* = 8.4 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.00 (s, 1H), 6.76 (t, *J* = 7.5 Hz, 1H), 6.41 (d, *J* = 7.8 Hz, 2H), 5.11 (s, 1H), 4.45 (d, *J* = 7.2 Hz, 1H), 2.76–2.79 (m, 2H), 2.53–2.57 (m, 2H), 2.39 (s, 3H), 2.31 (s, 3H), 1.73–1.75 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.7, 143.6, 140.3, 135.18, 135.15, 132.5, 131.0, 129.5, 129.4, 127.4, 126.0, 118.1, 117.5, 113.2, 85.7, 59.9, 47.5, 23.5, 21.7, 21.2; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₉N₃O₂SNa 470.1878; Found 470.1882.

trans-5-Methoxy-N-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4hdg)



The reaction was performed according to the general procedure A using 499 mg (1.0 mmol) of **1h** and 0.091 mL (1.0 mmol) of **2d** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4hdg** (312 mg, 0.67 mmol, 67% yield) as a pale beige solid.

Pale beige solid (312 mg, 0.67 mmol, 67% yield; mp 129–131 °C, dec.); IR (KBr) v: 3408, 3049, 3026, 2970, 2870, 2833, 2798, 1348, 1228, 1167, 1034, 750, 696 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.64 (d, J = 9.0 Hz, 1H), 7.38 (d, J = 7.8 Hz, 2H), 7.19 (t, J = 7.5 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 6.93 (dd, J = 8.7, 2.7 Hz, 1H), 6.76 (t, J = 7.5 Hz, 1H), 6.73 (d, J = 3.0 Hz, 1H), 6.39 (d, J = 7.8 Hz, 2H), 5.08 (s, 1H), 4.44 (d, J = 7.8 Hz, 1H), 3.77 (s, 3H), 2.76–2.78 (m, 2H), 2.55–2.57 (m, 2H), 2.40 (s, 3H), 1.72–1.77 (m, 4H); ¹³C{¹H} NMR (151 MHz,

CDCl₃) *δ* 157.7, 145.6, 143.6, 136.0, 135.0, 133.9, 129.5, 129.4, 127.4, 118.9, 118.2, 116.0, 113.3, 110.4, 85.8, 60.1, 55.7, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₉N₃O₃SNa 486.1827; Found 486.1827.

trans-4-Chloro-N-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4idg)

NH

Тś

trans-4idg *linear cis*-4idg *(trans:cis*=>20:<1)

The reaction was performed according to the general procedure B using 306 mg (1.0 mmol) of **S1i** and 0.091 mL (1.0 mmol) of **2d**. The residue was purified by silica-gel column chromatography using hexane/AcOEt (20/1-8/1 [v/v]) and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-4idg (212 mg, 0.45 mmol, 45% yield) as a pale beige solid.

Τś

Pale beige solid (212 mg, 0.45 mmol, 45% yield; mp 134–136 °C, dec.); IR (KBr) v: 3406, 3095, 3047, 3030, 2970, 2927, 2875, 2856, 2804, 1356, 1169, 760, 704 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.62 (d, *J* = 8.4 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.32 (t, *J* = 7.8 Hz, 1H), 7.22 (t, *J* = 8.1 Hz, 2H), 7.11 (d, *J* = 8.4 Hz, 2H), 7.08 (d, *J* = 7.8 Hz, 1H), 6.79 (t, *J* = 7.2 Hz, 1H), 6.47 (d, *J* = 7.2 Hz, 2H), 5.22 (s, 1H), 4.60 (d, *J* = 6.0 Hz, 1H), 2.76–2.79 (m, 2H), 2.53–2.56 (m, 2H), 2.40 (s, 3H), 1.74–1.79 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.7, 144.05, 144.05, 135.0, 131.6, 131.4, 130.2, 129.6, 129.4, 127.5, 125.5, 118.3, 115.8, 113.3, 86.0, 59.2, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆ClN₃O₂SNa 490.1332, 492.1302; Found 490.1335, 492.1301.

trans-6-Chloro-N-phenyl-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4jdg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1j** and 0.091 mL (1.0 mmol) of **2d** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4jdg** (375 mg, 0.80 mmol, 80% yield) as a pale beige solid.

Pale beige solid (375 mg, 0.80 mmol, 80% yield; mp 127–129 °C, dec.); IR (KBr) v: 3406, 3101, 3066, 3028, 2970, 2925, 2871, 2850, 1352, 1165, 758, 702 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, J = 1.8 Hz, 1H), 7.44 (d, J = 7.8 Hz, 2H), 7.21 (t, J = 7.2 Hz, 2H), 7.12–7.14 (m, 3H), 7.08 (dd, J = 7.8, 1.8 Hz, 1H), 6.78 (t, J =

7.2 Hz, 1H), 6.41 (d, J = 7.2 Hz, 2H), 5.17 (s, 1H), 4.47 (d, J = 7.8 Hz, 1H), 2.76–2.79 (m, 2H), 2.54–2.57 (m, 2H), 2.41 (s, 3H), 2.39 (d, J = 7.2 Hz, 1H), 1.74–1.79 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.4, 144.1, 143.8, 136.0, 135.0, 130.9, 129.7, 129.5, 127.4, 126.4, 125.5, 118.5, 118.0, 113.3, 86.4, 59.3, 47.5, 23.5, 21.7; HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₅H₂₆ClN₃O₂SNa 490.1332, 492.1302; Found 490.1331, 492.1306.

trans-N-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4ajg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.096 mL (1.0 mmol) of **2j** for 2 h. The residue was purified by recrystallization using hexane/ethanol (2/1 [v/v]) to give *trans*-**4ajg** (365 mg, 0.81 mmol, 81% yield) as a white solid.

White solid (365 mg, 0.81 mmol, 81% yield; mp 139–141 °C, dec.); IR (KBr) v: 3415, 3028, 2960, 2924, 2866, 1350, 1167, 764, 708 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.73 (d, *J* = 8.4 Hz, 1H), 7.40 (d, *J* = 7.8 Hz, 2H), 7.38 (td, *J* = 8.7, 1.5 Hz, 1H), 7.20 (dd, *J* = 7.8, 0.6 Hz, 1H), 7.12 (td, *J* = 8.4, 0.9 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 2H), 6.91 (t, *J* = 8.7 Hz, 2H), 6.33–6.37 (m, 2H), 5.10 (s, 1H), 4.43 (d, *J* = 7.2 Hz, 1H), 2.76–2.79 (m, 2H), 2.53–2.56 (m, 2H), 2.38 (s, 3H), 2.30 (d, *J* = 7.2 Hz, 1H), 1.71–1.76 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 156.2 (d, *J*_{C-F} = 235.7 Hz), 143.8, 142.6, 141.9, 135.1, 132.3, 130.3, 129.5, 127.4, 125.4 (d, *J*_{C-F} = 17.4 Hz), 117.8, 116.0, 115.8, 114.0 (d, *J*_{C-F} = 7.2 Hz), 85.3, 60.3, 47.4, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆FN₃O₂SNa 474.1627; Found 474.1632.

trans-N-(4-Chlorophenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4akg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 128 mg (1.0 mmol) of **2k** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4akg** (410 mg, 0.88 mmol, 88% yield) as a white solid.

White solid (410 mg, 0.88 mmol, 88% yield; mp 154–156 °C, dec.); IR (KBr) v: 3402, 3068, 3026, 2972, 2918, 2856, 1350, 1168, 758, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, *J* = 7.8 Hz, 1H), 7.37–7.41 (m, 3H), 7.20 (d, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 9.0 Hz, 2H), 7.12 (td, *J* = 6.9, 1.2 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 2H), 6.33 (d, *J* = 8.4 Hz, 2H), 5.08 (s, 1H), 4.44 (d, *J* = 7.2 Hz, 1H), 2.75–2.78 (m, 2H) 2.53–2.55 (m, 2H), 2.39 (d, *J* = 7.2 Hz, 1H), 2.38 (s, 3H), 1.72–1.76 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.2, 143.8, 142.7, 135.1, 132.1, 130.5, 129.5, 129.3, 127.3, 125.51, 125.46, 122.8, 117.9, 114.3, 85.2, 59.9, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆ClN₃O₂SNa 490.1332, 492.1302; Found 490.1328, 492.1305.





The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 172 mg (1.0 mmol) of **2l** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4alg** (447 mg, 0.87 mmol, 87% yield) as a white solid.

White solid (447 mg, 0.87 mmol, 87% yield; mp 151–153 °C, dec.); IR (KBr) v: 3402, 3070, 3022, 2970, 2918, 2856, 1350, 1169, 758, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, *J* = 7.8 Hz, 1H), 7.39 (td, *J* = 8.4, 1.5 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.28 (d, *J* = 9.0 Hz, 2H), 7.20 (d, *J* = 7.2 Hz, 1H), 7.12 (td, *J* = 8.4, 0.9 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 2H), 6.29 (d, *J* = 8.4 Hz, 2H), 5.07 (s, 1H), 4.43 (d, *J* = 7.2 Hz, 1H), 2.75–2.78 (m, 2H), 2.52–2.55 (m, 2H), 2.41 (d, *J* = 7.2 Hz, 1H), 2.38 (s, 3H), 1.71–1.78 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.6, 143.8, 142.7, 135.1, 132.1, 132.0, 130.4, 129.5, 127.3, 125.51, 125.47, 117.9, 114.9, 109.9, 85.3, 59.9, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆BrN₃O₂SNa 534.0827, 536.0806; Found 534.0827, 536.0809.





The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 138 mg (1.0 mmol) of **2m** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4amg** (256 mg, 0.53 mmol, 53% yield) as a pale green solid.

Pale green solid (256 mg, 0.53 mmol, 53% yield; mp 139–141 °C, dec.); IR (KBr) v: 3340, 3078, 2968, 2920, 2879, 2841, 1518, 1352, 1311, 1171, 752, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 8.12 (d, *J* = 9.0 Hz, 2H), 7.78 (d, *J* = 8.4 Hz, 1H), 7.45 (td, *J* = 8.4, 1.2 Hz, 1H), 7.37 (d, *J* = 8.4 Hz, 2H), 7.23 (dd, *J* = 7.8, 0.6 Hz, 1H), 7.17 (td, *J* = 8.4, 0.9 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.36 (d, *J* = 9.0 Hz, 2H), 5.06 (s, 1H), 4.53 (d, *J* = 6.6 Hz, 1H), 3.07 (d, *J* = 6.6 Hz, 1H), 2.77–2.80 (m, 2H), 2.54–2.57 (m, 2H), 2.40 (s, 3H), 1.74–1.79 (m, 4H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 150.7, 144.0, 142.9, 139.1, 135.0, 131.0, 130.8, 129.7, 127.3, 126.4, 125.8, 125.5, 118.3, 112.0, 85.3, 59.9, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆N₄O₄SNa 501.1572; Found 501.1572.

trans-N-(3-Chlorophenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4ang)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.105 mL (1.0 mmol) of **2n** for 1 h. The residue was purified by recrystallization using hexane/ethanol (2/1 [v/v]) and silica-gel column chromatography using hexane/AcOEt (10/1-8/1 [v/v]) to give *trans*-**4ang** (455 mg, 0.97 mmol, 97% yield) as a white solid.

White solid (455 mg, 0.97 mmol, 97% yield; mp 148–150 °C, dec.); IR (KBr) v: 3427, 3095, 3024, 2964, 2922, 2870, 2844, 1348, 1169, 758, 708 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, *J* = 8.4 Hz, 1H), 7.40 (td, *J* = 7.8, 1.2 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 7.8 Hz, 1H), 7.09–7.15 (m, 4H), 6.72 (ddd, *J* = 8.1, 2.1, 0.6 Hz, 1H), 6.34 (dd, *J* = 8.1, 1.5 Hz, 1H), 6.25 (t, *J* = 2.1 Hz, 1H), 5.06 (s, 1H), 4.45 (d, *J* = 7.2 Hz, 1H), 2.75–2.79 (m, 2H), 2.52–2.56 (m, 2H), 2.41 (s, 3H), 2.39 (d, *J* = 7.2 Hz, 1H), 1.72–1.77 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 146.6, 144.0, 142.8, 135.1, 135.0, 132.0, 130.50, 130.47, 129.7, 127.3, 125.53, 125.48, 118.1, 118.0, 113.9, 110.9, 85.2, 59.8, 47.5, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₅H₂₆ClN₃O₂SNa 490.1332, 492.1302; Found 490.1333, 492.1305.

trans-N-(2-Chlorophenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4aog)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.105 mL (1.0 mmol) of **2o** for 3 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4aog** (412 mg, 0.88 mmol, 88% yield) as a white solid.

White solid (412 mg, 0.88 mmol, 88% yield; mp 149–151 °C, dec.); IR (KBr) v: 3419, 3032, 2972, 2918, 2871, 2843, 1350, 1165, 754, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, *J* = 7.8 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.39 (td, *J* = 8.1, 0.9 Hz, 1H), 7.19–7.24 (m, 3H), 7.13 (t, *J* = 7.5 Hz, 1H), 7.05 (d, *J* = 8.4 Hz, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 6.72 (td, *J* = 8.7, 1.2 Hz, 1H), 5.22 (s, 1H), 4.49 (d, *J* = 6.0 Hz, 1H), 3.36 (d, *J* = 6.0 Hz, 1H), 2.80–2.83 (m, 2H), 2.57–2.61 (m, 2H), 2.32 (s, 3H), 1.74–1.79 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.2, 142.8, 142.0, 134.8, 131.6, 130.5, 129.7, 129.4, 128.2, 127.2, 125.6, 125.4, 118.9, 118.2, 117.4, 112.3, 85.7, 60.3, 47.4, 23.5, 21.8; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₇ClN₃O₂S 468.1513, 470.1483; Found 468.1516, 470.1478.

trans-N-(2,4-Dibromophenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4apg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 251 mg (1.0 mmol) of **2p** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4apg** (371 mg, 0.63 mmol, 63% yield) as a white solid.

White solid (371 mg, 0.63 mmol, 63% yield; mp 152–154 °C, dec.); IR (KBr) v: 3398, 3032, 2970, 2912, 2841, 1354, 1171, 756, 704 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.41 (d, J = 7.8 Hz, 2H), 7.39 (td, J = 8.4, 1.2 Hz, 1H), 7.37 (dd, J = 8.7, 2.1 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 7.14 (td, J = 7.8, 0.9 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 1H), 5.17 (s, 1H), 4.43 (d, J = 5.4 Hz, 1H), 3.41 (d, J = 5.4 Hz, 1H), 2.79–2.82 (m, 2H), 2.56–2.60 (m, 2H), 2.32 (s, 3H), 1.73–1.81 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.2, 142.8, 142.2, 134.8, 134.6, 131.8, 131.1, 130.6, 129.8, 127.2, 125.48,

125.45, 117.5, 113.5, 109.6, 109.3, 85.5, 60.6, 47.4, 23.5, 21.9; HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₅H₂₅Br₂N₃O₂SNa 611.9932; Found 611.9932.



trans-N-(3,5-Dimethoxyphenyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4aqg)

The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 153 mg (1.0 mmol) of **2q** for 3 h. The residue was purified by recrystallization using hexane/ethanol (2/1 [v/v]) and silica-gel column chromatography using hexane/AcOEt (6/1-4/1 [v/v]) to give *trans*-**4aqg** (282 mg, 0.57 mmol, 57% yield) as a white solid.

White solid (282 mg, 0.57 mmol, 57% yield; mp 139–141 °C, dec.); IR (KBr) v: 3413, 2958, 2933, 2875, 2839, 1348, 1248, 1168, 1066, 754 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, *J* = 8.4 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.37 (td, *J* = 8.4, 1.2 Hz, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 7.10–7.12 (m, 3H), 5.94 (t, *J* = 2.1 Hz, 1H), 5.69 (d, *J* = 1.8 Hz, 2H), 5.19 (s, 1H), 4.48 (d, *J* = 7.2 Hz, 1H), 3.77 (s, 6H), 2.76–2.81 (m, 2H), 2.55–2.59 (m, 2H), 2.49 (d, *J* = 7.2 Hz, 1H), 2.37 (s, 3H), 1.69–1.76 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 161.8, 147.6, 143.7, 142.7, 135.0, 132.2, 130.3, 129.5, 127.4, 125.6, 125.4, 117.8, 92.2, 90.7, 85.8, 60.0, 55.3, 47.4, 23.5, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₇H₃₁N₃O₄SNa 156.1933; Found 156.1930.

trans-2'-(Pyrrolidin-1-yl)-1'-tosyl-1,3'-biindoline (4afg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.111 mL (1.0 mmol) of **2f** for 2 h. The residue was purified by recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4afg** (413 mg, 0.90 mmol, 90% yield) as a white solid.

White solid (413 mg, 0.90 mmol, 90% yield; mp 141–143 °C, dec.); IR (KBr) v: 2976, 2943, 2902, 2868, 2837, 2738, 2677, 1338, 1169, 758, 708 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.71 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.35 (td, J = 8.4, 1.2 Hz, 1H), 7.14 (t, J = 6.9 Hz, 1H), 7.11 (d, J = 9.6 Hz, 1H), 7.09 (d, J = 8.4 Hz,

2H), 7.05 (td, J = 8.4, 1.5 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.70 (td, J = 7.8, 0.9 Hz, 1H), 5.33 (d, J = 1.2 Hz, 1H), 4.48 (s, 1H), 2.79–2.83 (m, 2H), 2.69 (q, J = 9.6 Hz, 1H), 2.56–2.63 (m, 3H), 2.33 (s, 3H), 1.72–1.77 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 151.2, 143.6, 142.9, 136.1, 130.2, 130.0, 129.30, 129.27, 127.7, 127.6, 126.8, 124.5, 124.2, 118.2, 116.7, 107.5, 85.7, 63.5, 49.4, 47.3, 28.3, 23.6, 21.6; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₇H₂₉N₃O₂SNa 482.1878; Found 482.1883.

trans-2,3-Di(pyrrolidin-1-yl)-1-tosylindoline (4agg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.083 mL (1.0 mmol) of **2g** for 2 h. The residue was purified by silica-gel column chromatography using hexane/AcOEt (3/1-1/1 [v/v]) and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4agg** (366 mg, 0.90 mmol, 90% yield) as a beige solid.

Beige solid (366 mg, 0.90 mmol, 90% yield; mp 98–100 °C, dec.); IR (KBr) v: 3066, 3035, 2966, 2925, 2873, 2819, 2796, 1352, 1167, 756, 704 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.62 (d, *J* = 7.8 Hz, 2H), 7.57 (d, *J* = 7.8 Hz, 1H), 7.24 (td, *J* = 8.4, 1.2 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 7.05 (d, *J* = 7.8 Hz, 2H), 6.99 (td, *J* = 8.7, 0.9 Hz, 1H), 5.22 (s, 1H), 3.45 (s, 1H), 2.69–2.72 (m, 2H), 2.41–2.47 (m, 4H), 2.28 (s, 3H), 2.11–2.14 (m, 2H), 1.63–1.67 (m, 4H), 1.49–1.52 (m, 2H), 1.38–1.42 (m, 2H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 143.2, 142.6, 136.0, 132.0, 129.2, 128.8, 127.7, 126.7, 123.8, 116.6, 84.7, 69.3, 51.0, 47.5, 23.2, 23.0, 21.5; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₉N₃O₂SNa 434.1878; Found 434.1877.

trans-3-(Piperidin-1-yl)-2-(pyrrolidin-1-yl)-1-tosylindoline (4ahg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.099 mL (1.0 mmol) of **2h** for 6 h. The residue was purified by silica-gel column chromatography using hexane/AcOEt (6/1-1/1 [v/v]) and methanol and recrystallization using hexane/isopropanol (2/1 [v/v]) to give *trans*-**4ahg** (421 mg, 0.99 mmol, 99% yield) as a pale beige solid.

Pale beige solid (421 mg, 0.99 mmol, 99% yield; mp 102–104 °C, dec.); IR (KBr) v: 3066, 3032, 2964, 2937, 2873, 2848, 2800, 2740, 1352, 1167, 752, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.71 (d, *J* = 7.8 Hz, 2H),

7.56 (d, J = 7.8 Hz, 1H), 7.23 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.11 (d, J = 9.0 Hz, 2H), 6.98 (t, J = 7.5 Hz, 1H), 5.29 (s, 1H), 3.60 (s, 1H), 2.71–2.74 (m, 2H), 2.47–2.51 (m, 2H), 2.29 (s, 3H), 2.15–2.18 (m, 2H), 2.05-2.06 (m, 2H), 1.59–1.68 (m, 4H), 1.29 (br s, 4H), 1.22–1.23 (m, 2H); $^{13}C{^{1}H}$ NMR (151 MHz, CDCl₃) δ 143.6, 142.7, 136.4, 130.3, 129.4, 129.2, 127.9, 127.3, 123.5, 115.8, 83.3, 71.1, 51.1, 47.3, 26.1, 24.6, 23.4, 21.6; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₄H₃₁N₃O₂SNa 448.2035; Found 448.2037.

4-(trans-2-(Pyrrolidin-1-yl)-1-tosylindolin-3-yl)morpholine (4aig)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.087 mL (1.0 mmol) of **2i** for 6 h. The residue was purified by silica-gel column chromatography using hexane/AcOEt (6/1-1/6 [v/v]) and methanol to give *trans*-**4aig** (411 mg, 0.96 mmol, 96% yield) as brown oil.

Brown oil (411 mg, 0.96 mmol, 96% yield); IR (KBr) v: 3064, 3030, 2958, 2854, 2763, 2690, 1354, 1165, 756, 706 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.29 (td, *J* = 8.4, 1.2 Hz, 1H), 7.13-7.16 (m, 3H), 7.02 (td, *J* = 7.5, 0.6 Hz, 1H), 5.24 (s, 1H), 3.54 (s, 1H), 3.41-3.44 (m, 2H), 3.30–3.31 (m, 2H), 2.73–2.74 (m, 2H), 2.49–2.50 (m, 2H), 2.32 (s, 3H), 2.29–2.31 (m, 2H), 2.10–2.13 (m, 2H), 1.66–1.69 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 143.4, 142.6, 136.0, 129.5, 129.12, 129.07, 127.6, 127.2, 123.6, 116.2, 83.2, 70.5, 66.6, 50.3, 47.2, 23.1, 21.3; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₃₀N₃O₃S 428.2008; Found 428.2013.

trans-3-(4-Methylpiperazin-1-yl)-2-(pyrrolidin-1-yl)-1-tosylindoline (4arg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.110 mL (1.0 mmol) of **2r** for 6 h. The residue was purified by silica-gel column chromatography using chloroform/methanol (10/1-8/1 [v/v]) and recrystallization using hexane/diethyl ether (2/1 [v/v]) to give *trans*-**4arg** (146 mg, 0.33 mmol, 33% yield) as a pale beige solid.

Pale beige solid (146 mg, 0.33 mmol, 33% yield; mp 120–122 °C, dec.); IR (KBr) v: 3068, 3033, 2966, 2933, 2877, 2839, 2798, 2746, 2686, 1342, 1167, 752, 704 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.64 (d, *J* = 8.4 Hz,

2H), 7.59 (d, J = 8.4 Hz, 1H), 7.24 (td, J = 8.7, 1.2 Hz, 1H), 7.13 (d, J = 7.2 Hz, 1H), 710 (d, J = 7.8 Hz, 2H), 6.99 (td, J = 7.2, 0.9 Hz, 1H), 5.22 (d, J = 0.6 Hz, 1H), 3.54 (s, 1H), 2.69–2.72 (m, 2H), 2.45–2.49 (m, 2H), 2.29 (br s, 5H), 2.14–2.17 (m, 6H), 1.60–1.68 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 143.3, 142.7, 136.2, 129.8, 129.5, 129.3, 127.8, 127.3, 123.6, 116.2, 83.5, 70.4, 54.9, 49.6, 47.3, 45.9, 23.3, 21.5; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₃₃N₄O₂S 441.2324; Found 441.2323.

trans-N-(tert-Butyl)-2-(pyrrolidin-1-yl)-1-tosylindolin-3-amine (4abg)



The reaction was performed according to the general procedure A using 469 mg (1.0 mmol) of **1a** and 0.106 mL (1.0 mmol) of **2b** for 2 h. The residue was purified by silica-gel column chromatography using hexane/AcOEt (10/1-8/1 [v/v]) to give *trans*-**4abg** (7.1 mg, 0.02 mmol, trace) as a dark red oil.

Dark red oil (7.1 mg, 0.02 mmol, trace); IR (KBr) v: 3338, 3066, 2964, 2931, 2873, 1354, 1167, 754, 708 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.58–7.61 (m, 3H), 7.24 (td, J = 8.7, 1.2 Hz, 1H), 7.12 (d, J = 9.0 Hz, 2H), 7.04– 7.08 (m, 2H), 5.01 (s, 1H), 3.89 (s, 1H), 2.70–2.74 (m, 2H), 2.46–2.49 (m, 2H), 2.30 (s, 3H), 1.64–1.69 (m, 4H), 1.02 (s, 9H), 0.97 (s, 1H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 143.6, 142.0, 135.7, 135.3, 129.3, 129.1, 128.0, 125.11, 125.05, 117.1, 90.1, 59.6, 51.4, 47.7, 29.9, 23.4, 21.6; HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₃H₃₁N₃O₂SNa 436.2035; Found 436.2034.

Scheme S5 Gram-scale synthesis of 2,3-diaminoindolines



To a suspension of *trans*-1a (9.39 g, 20 mmol) and 2e (2.16 mL, 1.0 equiv., 20 mmol) in AcOEt (100 mL, 0.2 M) was added Et₃N (5.54 mL, 2.0 equiv., 40 mmol). The suspension was stirred at reflux in an oil bath for 2 h. Then 2g (1.74 mL, 1.05 equiv., 21 mmol) was added to the mixture and stirred for a further 1 h. After the whole was cooled to room temperature, the resulting mixture was concentrated *in vacuo*. The residue was purified by recrystallization using (EtOH/hexane) to give *trans*-4aeg (8.78 g, 19.6 mmol, 98%) as a white solid.

Scheme S6 Follow up chemistry

N-Methyl-N-phenyl-2-(pyrrolidin-1-yl)-1-tosyl-1H-indol-3-amine (5aeg)



To a mixture of *trans*-4aeg (448 mg, 1.0 mmol) and MnO_2 (869 mg, 10 equiv., 10 mmol) was added DCE (5.0 mL, 0.2 M). The suspension was stirred at reflux in oil bath for 4 h. After the whole was cooled to room temperature, the mixture was filtered through a celite pad. The resulting filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (10/1 v/v) to give 5aeg (384 mg, 0.86 mmol, 86% yield) as a white solid.

White solid (384 mg, 0.86 mmol, 86% yield; mp 153–155 °C); IR (KBr) v: 3062, 3026, 2972, 2929, 2871, 1363, 1173, 754 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 8.20 (d, *J* = 8.4 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.24 (td, *J* = 7.8, 1.2 Hz, 1H), 7.19 (d, *J* = 7.8 H, 2H), 7.14 (td, *J* = 7.8, 0.6 Hz, 1H), 7.09 (t, *J* = 7.8 Hz, 2H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.72 (t, *J* = 7.2 Hz, 1H), 6.33 (d, *J* = 7.8 Hz, 2H), 3.23 (br s, 4H), 3.12 (s, 3H), 2.42 (s, 3H), 1.87–1.85 (m, 4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 148.2, 144.4, 142.9, 134.7, 134.1, 129.9, 129.2, 128.9, 127.1, 124.5, 123.4, 117.8, 117.7, 117.1, 117.0, 112.5, 50.9, 39.9, 25.2, 21.7; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₇N₃O₂SNa 468.1722; Found 468.1725.

4-Methyl-N-(2-(1-(methyl(phenyl)amino)-2-(pyrrolidin-1-yl)ethyl)phenyl)benzenesulfonamide (6)



To a mixture of *trans*-4aeg (224 mg, 0.50 mmol) and *tert*-BuOK (168 mg, 3.0 equiv., 1.5 mmol) in MeOH (2.5 mL, 0.20 M) was added NaBH₄ (189 mg, 10 equiv., 5.0 mmol) under Ar atmosphere. The suspension was stirred at reflux in oil bath for 4 h. After the whole was cooled to room temperature, H₂O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by recrystallization using methanol to give **6** (165 mg, 0.73 mmol, 73% yield) as a white solid.

White solid (165 mg, 0.73 mmol, 73% yield; mp 119–121 °C); IR (KBr) v: 3057, 2951, 2897, 2875, 2831, 2509,

1333, 1159, 1092, 756 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 13.99 (br s,1H) 7.73 (d, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 8.4 Hz, 2H), 7.26 (d, *J* = 7.8 Hz, 2H), 7.20 (td, *J* = 8.4, 1.5 Hz, 1H), 7.03 (t, *J* = 7.8 Hz, 2H), 6.94 (t, *J* = 7.2 Hz, 1H), 6.90 (d, *J* = 6.6 Hz, 1H), 6.66 (t, *J* = 7.5 Hz, 1H), 6.19 (d, *J* = 7.8 Hz, 2H), 4.61 (d, *J* = 8.4 Hz, 1H), 3.26 (dd, *J* = 12.3, 1.2 Hz, 1H), 2.94 (s, 3H), 2.90 (d, *J* = 12.0 Hz, 1H), 2.84–2.85 (m, 2H), 2.62 (br s, 2H), 2.43 (s, 3H), 1.95–2.03 (m, 4H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 148.7, 143.0, 139.0, 136.8, 134.3, 129.8, 129.1, 128.1, 126.8, 126.7, 124.4, 123.1, 116.9, 112.2, 62.3, 58.2, 54.1, 35.0, 23.8, 21.8; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₂N₃O₂S 450.2215; Found 450.2217.

4-(1H-Indol-3-yl)-N-methylaniline (7)



trans-4aeg (44.7 mg, 0.10 mmol) and Et₃N (10.7 mg, 1.0 equiv., 0.10 mmol) were stirred at 100 °C in oil bath under solvent-free condition. Then, TfOH (0.5 mL) was added to the mixture and stirred for 1 minute. After the whole was cooled down to room temperature, the mixture was quenched with sat. NaHCO₃ (5 mL) and extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1–0/1 v/v) to give 7 (15.9 mg, 0.072 mmol, 72%) as a pale-yellow oil.

Pale-yellow oil (15.9 mg, 0.072 mmol, 72%); IR (KBr) v: 3357, 3153, 3099, 3055, 2916, 2858, 2816, 1506, 1246, 748 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (br s, 1H), 7.91 (d, *J* = 8.4 Hz, 1H), 7.51 (d, *J* = 9.0 Hz, 2H), 7.41 (d, *J* = 7.8 Hz, 1H), 7.27 (d, *J* = 2.4 Hz, 1H), 7.23 (dt, *J* = 7.2, 1.2 Hz, 1H), 7.17 (dt, *J* = 7.8, 1.2 Hz, 1H), 6.74 (d, *J* = 9.0 Hz, 2H), 3.79 (br s, 1H), 2.90 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 147.9, 136.7, 128.7, 126.2, 124.8, 122.3, 120.8, 120.06, 120.06, 118.8, 113.0, 111.4, 31.1; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₅N₂ 223.1235; Found 223.1242.

4-Methyl-N-(2-(1-methyl-1H-indol-2-yl)phenyl)benzenesulfonamide (8) [2c]



A solution of *trans*-4aeg (44.7 mg, 0.1 mmol) in HFIP (1.0 mL, 0.1 M) was stirred at reflux for 2 h. The resulting mixture was cooled to room temperature and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (4/1 v/v) to give **8** (29.6 mg, 0.079 mmol, 79% yield) as a white solid.

White solid (29.6 mg, 0.079 mmol, 79% yield; mp 145–147 °C); IR (KBr) v: 3261, 3097, 3068, 2981, 2939, 1477, 1335, 1163, 752 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.80 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.44–7.41 (m, 1H), 7.35–7.31 (m, 2H), 7.22 (ddd, J = 7.8, 6.0, 1.8 Hz, 1H), 7.19 (d, J = 4.2 Hz, 2H), 7.17 (d, J = 7.8 Hz, 2H), 7.12 (br s, 1H), 6.24 (s, 1H), 3.24 (s, 3H), 2.41 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 144.0, 137.9, 136.3, 135.9, 134.7, 131.4, 130.0, 129.7, 127.7, 127.2, 124.4, 123.3, 122.5, 120.9, 120.6, 120.4, 109.8, 102.6, 30.3, 21.6; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₀N₂O₂SNa 399.1143; Found 399.1139.

N-Phenyl-2-(pyrrolidin-1-yl)-3*H*-indol-3-imine (9)



To a mixture of *trans*-4adg (217 mg, 0.5 mmol) and MnO₂ (435 mg, 10 equiv., 5.0 mmol) was added DCE (5.0 mL, 0.1 M). The suspension was stirred at reflux in oil bath for 18 h. After the whole was cooled to room temperature, the mixture was filtered through a celite pad. The resulting filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography using AcOEt to give **9** (73.5 mg, 0.27 mmol, 53% yield) as a red solid.

Red solid (73.5 mg, 0.27 mmol, 53% yield; mp 150-152 °C); IR (KBr) v: 3033, 2966, 2916, 2871, 2852, 1616, 1560, 758, 704 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.41 (t, *J* = 7.8 Hz, 2H), 7.21 (t, *J* = 7.2 Hz, 1H), 7.17 (dt, *J* = 7.8, 1.2 Hz, 1H), 7.03 (d, *J* = 7.8 Hz, 1H), 6.91 (dd, *J* = 8.4, 1.2 Hz, 2H), 6.47 (dt, *J* = 7.2, 1.2 Hz, 1H), 6.32 (d, *J* = 7.8 Hz, 1H), 3.95 (t, *J* = 6.0 Hz, 2H), 3.85 (t, *J* = 6.6 Hz, 2H), 2.02 (q, *J* = 6.0 Hz, 2H), 1.98 (q, *J* = 6.6 Hz, 2H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 162.12, 162.12, 160.9, 150.6, 134.3, 129.5, 126.0, 124.7, 120.6, 120.5, 117.7, 117.4, 50.1, 49.0, 26.8, 24.1; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₈H₁₈N₃ 276.1501; Found 276.1496.

Reference

- 1) Tokushige, K., Abe, T. Asian J. Org. Chem. 2025, e202500439.
- 2) (a) Shu, C.; Li, L.; Xiao, X.; Yu, Y.; Ping, Y.; Zhou, J.; Ye, L. *Chem. Commun.* 2014, 50, 8689-8692; (b) Lin, Q.; Liu, Y.; Song, H.; Wang, Q.; *Adv. Synth. Catal.* 2020, *362*, 3110-3115; (c) Rivinoja, D.; Gee, Y.; Gardiner, M.; Ryan, J.; Hyland, C.; *ACS Catal.* 2017, *7*, 1053-1056; (d) Jayaraman, A.; Castro, L.; Fontaine, F.; *Org. Process Res. Dev.* 2018, *22*, 1489-1499; (e) Tokushige, K.; Kobori, Y.; Asai, S. Abe, T.; *Org. Biiomol. Chem.* 2024, *22*, 7343-7348.
- 3) (a) Abe, T.; Suzuki, T.; Anada, M.; Matsunaga, S.; Yamada, K. Org. Lett. 2017, 19, 4275–4278; (b) Abe, T.; Hirao, S.; Yamashiro, T. Chem. Commun. 2020, 56, 10183–10186; (c) Abe, T.; Yamashiro, T.; Shimizu, K.; Sawada, D. Chem. Eur. J. 2022, 28, e202201113; (d) Abe, T.; Yamada, K. Org. Lett. 2018, 20, 1469–1472.











S30











S35















































































































